The Journal of Nervous and Mental Disease
March 1, 2022
Kyle Possemato, Nina Silander, Nardos Bellete et al.
ABSTRACT: Although nightmares are known to predict the clinical course of posttraumatic stress disorder (PTSD), research on the relationship between specific nightmare characteristics and PTSD severity is sparse. This study conducted a secondary analysis to explore how five nightmare characteristics are cross-sectionally related to PTSD severity in 76 combat veterans with PTSD and at-risk...
Clinical drug investigation
March 1, 2022
Anton L. V. Avanceña, J. Kahn, Elliot Marseille
19 citations
Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to psychotherapy with placebo. This study estimates potential costs, health benefits, and net savings of expanding access to MDMA-AT to eligible US patients with chronic and severe PTSD. Using a...
JMIR Mental Health
February 28, 2022
Megan A Kirk, Bilal Taha, Kevin Dang et al.
Posttraumatic stress disorder (PTSD) is a debilitating, undertreated condition. The web-based delivery of cognitive behavioral therapy supplemented with mindfulness meditation and yoga is a viable treatment that emphasizes self-directed daily practice. This study aims to examine the effectiveness of a web-based cognitive behavioral therapy, mindfulness, and yoga (CBT-MY) program designed for...
PLoS One
February 25, 2022
Elliot Marseille, Jennifer Mitchell, James G. Kahn
49 citations
Background Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study updates the cost-effectiveness analysis of this novel therapy using data from a new phase 3...
Journal of Clinical Nursing
February 20, 2022
Hadassah Joann Ramachandran, Muhammad Shaheed Bin Mahmud, Priyadharshni Rajendran et al.
AIMS AND OBJECTIVES The aim of this study was to investigate the effectiveness of mindfulness-based interventions on psychological well-being, burnout and post-traumatic stress disorder symptoms among working registered nurses. BACKGROUND Nurses account for nearly half of the global healthcare workforce and are considered significant contributors in multi-disciplinary healthcare teams. Yet,...
Journal of Humanistic Psychology
February 10, 2022
Terence H. W. Ching, Monnica T. Williams, Sara Reed et al.
10 citations
MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was...
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
February 5, 2022
Sean Bentley, Hewa Artin, Eamonn Mehaffey et al.
Racemic (R,S)‐ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)‐ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment‐resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of...
Journal of Traumatic Stress
February 1, 2022
Mayer Bellehsen, Valentina Stoycheva, Barry H. Cohen et al.
Preliminary studies have demonstrated the efficacy of Transcendental Meditation (TM) for treating posttraumatic stress disorder (PTSD). The present study extended previous research with a pilot trial of TM as a treatment for PTSD via a single-blinded, randomized controlled design. veterans with PTSD (N = 40) were assigned to a TM intervention or treatment-as-usual (TAU) control group....
Expert Opinion on Investigational Drugs
February 1, 2022
Lynnette A. Averill, Chadi G. Abdallah
The unfortunate reality of the mental health crisis plaguing much of the world, in tandem with and exacerbated by the COVID-19 pandemic [1–3], highlights the limited effective pharmacologic treatments in our toolbox for posttraumatic stress disorder (PTSD). There are only two FDA-approved medications indicated for PTSD, both selective serotonin reuptake inhibitors (SSRIs). Though these...
Drug and Alcohol Dependence
February 1, 2022
Christopher R. Nicholas, Julie B. Wang, Allison R. Coker et al.
67 citations
Background Post-traumatic stress disorder (PTSD) is commonly associated with alcohol and substance use disorders (ASUD). A randomized, placebo-controlled, phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy (MDMA-AT) for the treatment of severe PTSD. This analysis explores patterns of alcohol and substance use in patients receiving MDMA-AT compared to placebo plus...